Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 6/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822737 | 1.00 | CTSS (0.42) | CTSSCTSKCCR9CCR2MCL1 | |
| SCHEMBL31689687 | 0.91 | NQO2 (0.37) | CTSSCTSKCCR9CCR2MCL1 | |
| SCHEMBL21822112 | 0.91 | NQO2 (0.37) | CTSSCTSKCCR9CCR2MCL1 | |
| SCHEMBL25016935 | 0.88 | F10 (0.43) | CCR2MCL1F10FDPSCMA1 | |
| SCHEMBL25015964 | 0.87 | CNR2 (0.39) | CTSSCTSKMCL1NQO2F10 | |
| SCHEMBL25016919 | 0.86 | CCR2 (0.39) | CCR9CCR2MCL1F10FDPS | |
| SCHEMBL25016775 | 0.86 | F10 (0.47) | F10 | |
| SCHEMBL25016107 | 0.85 | F10 (0.41) | NQO2F10 | |
| SCHEMBL25017943 | 0.85 | ACHE (0.43) | CTSSCTSKMCL1F10 | |
| SCHEMBL21822553 | 0.85 | NQO2 (0.44) | CTSSCTSKNQO2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | CTSS 610/4885CTSK 266/4885CCR9 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.